October 29, 2024, GlycoMimetics enters into acquisition agreement with Crescent biopharma.Crescent’s lead program CR-001, a tetravalent PD-1 x VEGF bispecific antibody incorporating the cooperative binding mechanism underpinning recent immuno-oncology breakthrough, expected to have preliminary proof of concept data in 2H26.
Indeed, treatment regimens including combinations of anti-PD-1/PD-L1 antibodies and VEGF antibodies have been approved for use in clinical settings for non-squamous non-small cell lung cancer (NSCLC) and hepatocellular carcinoma. Moreover, many clinical trials are currently underway, making it one of the most promising combinations in cancer immunotherapy.
